Table 3.
Hazard Ratios (HR) and 95% Confidence Intervals (CI) of Atrial Fibrillation (AF) Associated With FGF‐23 Concentrations by Method of AF Ascertainment, Atherosclerosis Risk in Communities Study, 1990–2010
| FGF‐23 (Linear)* | Log2(FGF‐23) | FGF‐23 (Quartiles) | ||||
|---|---|---|---|---|---|---|
| Q1 (2.9 to 33.8 pg/mL) | Q2 (33.9 to 41.8 pg/mL) | Q3 (41.9 to 51.6 pg/mL) | Q4 (51.7 to 242.7 pg/mL) | |||
| Events ascertained from hospital discharge codes | ||||||
| AF events | 1565 | 1565 | 339 | 365 | 380 | 481 |
| HR (95% CI) | 1.03 (0.98, 1.09) | 1.06 (0.96, 1.18) | 1 (ref) | 0.99 (0.85, 1.15) | 0.95 (0.82, 1.10) | 1.09 (0.94, 1.26) |
| Events ascertained from study ECG | ||||||
| AF events | 77 | 77 | 15 | 20 | 22 | 20 |
| HR (95% CI) | 0.91 (0.71, 1.17) | 0.91 (0.56, 1.48) | 1 (ref) | 1.20 (0.61, 2.37) | 1.10 (0.56, 2.15) | 0.84 (0.42, 1.72) |
Cox proportional hazards model adjusted for age, race, sex, study site, body mass index, smoking, education, height, diabetes, systolic and diastolic blood pressure, use of antihypertensive medication, prevalent coronary heart disease, prevalent heart failure, ECG‐based left ventricular hypertrophy, NT‐proBNP, high‐sensitivity C‐reactive protein, and eGFR. eGFR indicates estimated glomerular filtration rate; FGF, fibroblast growth factor; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide.
HR (95% CI) corresponds to a difference of 16 pg/mL.